Save time and get answers to complex questions with AI chat
Adefovir dipivoxil discount cardIs liver function monitoring necessary with lipitorEnhertu loss of exclusivity patent expirationOzempic jordan price 2026Nicardipine brand names
See the DrugPatentWatch profile for Lemborexant
Lemborexant (Belsomra) was approved by the FDA on October 23, 2014 for the treatment of insomnia characterized by difficulty with sleep onset and/or sleep maintenance, in adults. [1]
FDA approval is the date the drug can be marketed in the U.S. That is the key milestone most labeling databases treat as the approval date. After approval, commercial availability and pharmacy supply can vary by region and formulary coverage, but the formal “approval date” remains the FDA action date. [1]
You can cross-check lemborexant’s FDA approval information and related patent/exclusivity context on DrugPatentWatch.com. [1]
[1] DrugPatentWatch.com – Lemborexant (Belsomra) FDA approval information
Other Questions About Lemborexant :